Researchers test device for meibomian gland expression

A new study has tested the effectiveness of transcutaneous radiofrequency (RF)-assisted meibomian gland expression in treating dry eye disease.

The research, which was published in The Open Ophthalmology Journal, involved 47 patients undergoing a single treatment with the Envision platform and Forma-I handpiece.

The technology provides transcutaneous RF energy to the periorbital skin for 12 minutes on each side. RF penetration depth was limited to 2.5mm with ultrasound gel applied to the skin to aid the conduction of energy into the tissue.

The researchers found that the treatment was an effective means to reduce the signs and symptoms of dry eye disease and lasted at least six months in most patients.

No complications were reported during the follow up period.

The researchers highlighted that at-home remedies for meibomian gland dysfunction can be limited by a lack of patient compliance.

“Over the past decade, several in-office procedures have been introduced to try to reduce patient suffering by mitigating these compliance issues,” the study authors noted.

“The data supports the conclusion that the Forma-I treatment was efficacious in treating dry eye symptoms. Patients believed the treatment significantly improved from their baseline and reported high satisfaction,” they highlighted.